Home LiteratureArticle Details
PMID: 21539880 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Vaccine ·Vol. 29 ·No. 27 ·2011-06-15 ·Pages 4485-91

Haralambieva IH, Ovsyannikova IG, O'Byrne M, Pankratz VS, Jacobson RM, Poland GA

Abstract

The measurement of measles-specific neutralizing antibodies, directed against the surface measles virus hemagglutinin and fusion proteins, is considered the gold standard in measles serology. We assessed functional measles-specific neutralizing antibody levels in a racially diverse cohort of 763 young healthy adolescents after receipt of two doses of measles-mumps-rubella vaccine, by the use of an automated plaque reduction microneutralization (PRMN) assay, and evaluated their relevance to protective antibody levels, as well as their associations with demographic and clinical variables. We also concurrently assessed measles-specific IFNγ Elispot responses and their relation to the observed antibody concentrations. The geometric mean titer for our cohort was 832mIU/mL (95% CIs: 776; 891). Sixty-eight subjects (8.9%) had antibody concentrations of less than the protective threshold of 210mIU/mL (corresponding to PRMN titer of 120; suggesting protection against symptomatic disease), and 177 subjects (23.2%) demonstrated persisting antibody concentrations above 1841mIU/mL (corresponding to PRMN titer of 1052; suggesting total protection against viral infection), 7.4 years after vaccination, in the absence of wild-type virus boosting. The mean measles-specific IFNγ Elispot response for our cohort was 46 (95% CIs: 43; 49) IFNγ-positive spots per 200,000 cells with no relation of cellular immunity measures to the observed antibody concentrations. No significant associations between antibody titers and demographic and clinical variables, including gender and race, were observed in our study. In conclusion, in a large observational study of measles immunity, we used an automated high-throughput measles virus-specific neutralization assay to measure humoral immunity, and concurrently determined measles-specific cellular immunity to aid the assessment of potential susceptibility to measles in vaccinated populations.

MeSH Terms
Adolescent Adult Antibodies, Neutralizing/blood,immunology Antibodies, Viral/blood,immunology Antibody Specificity B-Lymphocytes/immunology Child Female High-Throughput Screening Assays/methods Humans Immunity, Cellular Immunization Male Measles/immunology,prevention & control,virology Measles virus/immunology Measles-Mumps-Rubella Vaccine/administration & dosage,immunology Neutralization Tests T-Lymphocytes/immunology Viral Plaque Assay Young Adult
Chemicals
Antibodies, Neutralizing Antibodies, Viral Measles-Mumps-Rubella Vaccine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Haralambieva Iana H
Mayo Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Ovsyannikova Inna G
O'Byrne Megan
Pankratz V Shane
Jacobson Robert M
Poland Gregory A
References (52)
52 references, click to expand
  1. Identification of an association between HLA class II alleles and low antibody levels after measles immunization.
    Vaccine. 2001 Nov 12;20(3-4):430-8 PMID: 11672906
  2. Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells.
    Scand J Clin Lab Invest. 2005;65(8):681-9 PMID: 16319042
  3. Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF).
    Transl Res. 2007 Jan;149(1):10-4 PMID: 17196517
  4. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity.
    Am J Epidemiol. 1999 Dec 1;150(11):1238-49 PMID: 10588085
  5. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine.
    Pediatrics. 2008 May;121(5):e1091-9 PMID: 18450852
  6. Measles outbreak associated with a church congregation: a study of immunization attitudes of congregation members.
    Public Health Rep. 2008 Mar-Apr;123(2):126-34 PMID: 18457065
  7. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population.
    Tissue Antigens. 2008 Sep;72(3):211-20 PMID: 18715339
  8. Sex differences in the humoral antibody response to live measles vaccine in young adults.
    Int J Epidemiol. 1994 Oct;23(5):1078-81 PMID: 7860159
  9. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody.
    J Clin Microbiol. 1995 Apr;33(4):811-5 PMID: 7790442
  10. Immunity against measles in school-aged children: implications for measles revaccination strategies.
    Can J Public Health. 1996 Nov-Dec;87(6):407-10 PMID: 9009400
  11. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    J Infect Dis. 2004 Jul 1;190(1):83-90 PMID: 15195246
  12. Persistence of measles antibody after revaccination.
    J Infect Dis. 1992 Jul;166(1):205-8 PMID: 1607699
  13. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
    Vaccine. 1994 Feb;12(2):129-33 PMID: 8147093
  14. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.
    Clin Diagn Lab Immunol. 2000 Jan;7(1):111-3 PMID: 10618288
  15. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Isr Med Assoc J. 2000 Mar;2(3):192-5 PMID: 10774264
  16. Measles--United States, January 1-April 25, 2008.
    MMWR Morb Mortal Wkly Rep. 2008 May 9;57(18):494-8 PMID: 18463608
  17. Global measles mortality, 2000-2008.
    MMWR Morb Mortal Wkly Rep. 2009 Dec 4;58(47):1321-6 PMID: 19959985
  18. Measles antibody: reevaluation of protective titers.
    J Infect Dis. 1990 Nov;162(5):1036-42 PMID: 2230231
  19. Update: multistate outbreak of mumps--United States, January 1-May 2, 2006.
    MMWR Morb Mortal Wkly Rep. 2006 May 26;55(20):559-63 PMID: 16723967
  20. Association of parental vaccination reports with measles, mumps, and rubella protective antibody levels: comparison of Somali immigrant, Hispanic migrant, and US children in Rochester, Minn.
    Mayo Clin Proc. 2002 Mar;77(3):241-5 PMID: 11888027
  21. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation.
    J Med Microbiol. 1999 Dec;48(12):1075-1080 PMID: 10591160
  22. Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity.
    Clin Vaccine Immunol. 2008 Jul;15(7):1054-9 PMID: 18463223
  23. An evaluation of nine commercial EIA kits for the detection of measles specific IgG.
    J Virol Methods. 1997 Jun;66(1):51-9 PMID: 9220390
  24. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Pediatr Infect Dis J. 1996 Aug;15(8):687-92 PMID: 8858673
  25. Race: a risk factor for dengue hemorrhagic fever.
    Arch Virol. 2007;152(3):533-42 PMID: 17106622
  26. Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development.
    Cancer Immunol Immunother. 2008 Jan;57(1):107-14 PMID: 17618436
  27. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay.
    J Virol Methods. 2006 Feb;131(2):209-12 PMID: 16188328
  28. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
    Vaccine. 2002 Jan 15;20(7-8):1134-40 PMID: 11803074
  29. Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test.
    Diagn Microbiol Infect Dis. 1999 Mar;33(3):147-52 PMID: 10092962
  30. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated.
    Pediatrics. 2010 Apr;125(4):747-55 PMID: 20308208
  31. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.
    Vaccine. 2000 Oct 15;19(4-5):523-9 PMID: 11027817
  32. Sexual dimorphism of humoral immunity with human vaccines.
    Vaccine. 2008 Jul 4;26(29-30):3551-5 PMID: 18524433
  33. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study.
    Eur J Clin Microbiol Infect Dis. 2006 May;25(5):310-7 PMID: 16786377
  34. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
    Arch Pediatr Adolesc Med. 2007 Mar;161(3):294-301 PMID: 17339511
  35. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.
    J Infect Dis. 1995 Dec;172(6):1591-5 PMID: 7594723
  36. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults.
    Vaccine. 2006 Aug 14;24(33-34):5913-8 PMID: 16759768
  37. The plaque-neutralization test as a measure of prior exposure to measles virus.
    J Infect Dis. 1987 Jan;155(1):146-9 PMID: 3794399
  38. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal.
    Pediatr Infect Dis J. 1995 Mar;14(3):203-9 PMID: 7761185
  39. Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees.
    Cytokine. 2010 Apr;50(1):24-9 PMID: 20117947
  40. Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project.
    Vaccine. 2008 Jun 25;26(27-28):3534-9 PMID: 18490082
  41. Racial differences in HLA class II associations with hepatitis C virus outcomes.
    J Infect Dis. 2001 Jul 1;184(1):16-21 PMID: 11398104
  42. Measles control--can measles virus inhibitors make a difference?
    Curr Opin Investig Drugs. 2009 Aug;10(8):811-20 PMID: 19649926
  43. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination.
    Vaccine. 2007 Dec 21;26(1):59-66 PMID: 18063236
  44. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
    J Infect Dis. 2001 Oct 1;184(7):817-26 PMID: 11528592
  45. Neutralizing B cell response in measles.
    Viral Immunol. 2002;15(3):451-71 PMID: 12479395
  46. Seroprevalence of measles antibody in the US population, 1999-2004.
    J Infect Dis. 2007 Nov 15;196(10):1459-64 PMID: 18008224
  47. Gender effects on humoral immune responses to smallpox vaccine.
    Vaccine. 2009 May 26;27(25-26):3319-23 PMID: 19200827
  48. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects.
    Vaccine. 1999 Mar 17;17(11-12):1525-31 PMID: 10195789
  49. Progress in global measles control and mortality reduction, 2000-2007.
    MMWR Morb Mortal Wkly Rep. 2008 Dec 5;57(48):1303-6 PMID: 19052529
  50. Ethnicity greatly influences cytokine gene polymorphism distribution.
    Am J Transplant. 2002 Jul;2(6):560-7 PMID: 12118901
  51. Role of virus strain in conventional and enhanced measles plaque neutralization test.
    J Virol Methods. 1981 Dec;3(5):251-60 PMID: 7334066
  52. Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines.
    Vaccine. 2010 Jun 23;28(29):4588-92 PMID: 20470793
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
1873-2518
DOI
10.1016/j.vaccine.2011.04.037
Published
2011-06-15
Epub
2011-00-01
Pages
4485-91
Language
English
Region
Netherlands
NLM ID
8406899
PMCID
PMC3117252
Subset
IM
Grants
NIAID NIH HHS · R01 AI033144-16 · United States
NCRR NIH HHS · 1 UL1 RR024150-01 · United States
NIAID NIH HHS · R01 AI033144-13 · United States
NIAID NIH HHS · R01 AI033144-06 · United States
NIAID NIH HHS · R01 AI033144-17 · United States
NIAID NIH HHS · R01 AI048793-04 · United States
NIAID NIH HHS · R01 AI033144-07 · United States
NIAID NIH HHS · R01 AI048793-03 · United States
NIAID NIH HHS · R01 AI033144-11 · United States
NIAID NIH HHS · R01 AI033144-09 · United States
NIAID NIH HHS · AI 33144 · United States
NIAID NIH HHS · R01 AI048793-01 · United States
NIAID NIH HHS · R01 AI033144-12 · United States
NIAID NIH HHS · R01 AI033144 · United States
NIAID NIH HHS · R01 AI033144-18 · United States
NIAID NIH HHS · R01 AI048793 · United States
NCRR NIH HHS · UL1 RR024150 · United States
NIAID NIH HHS · R01 AI033144-14A2 · United States
NIAID NIH HHS · R01 AI033144-15 · United States
NIAID NIH HHS · R01 AI033144-08 · United States
NIAID NIH HHS · R01 AI048793-05 · United States
NIAID NIH HHS · R01 AI048793-02 · United States
NIAID NIH HHS · R37 AI048793 · United States
NIAID NIH HHS · R01 AI033144-10 · United States
NIAID NIH HHS · AI 48793 · United States
External Links
PubMed source DOI: 10.1016/j.vaccine.2011.04.037 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2